Volume 2 Supplement 3

Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

Open Access

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2

  • Howard L Kaufman1,
  • Sandra Aung2,
  • Michael Morse3,
  • Michael Wong4,
  • James Lowder5,
  • Gregory Daniels6 and
  • David McDermott7
Journal for ImmunoTherapy of Cancer20142(Suppl 3):P88

DOI: 10.1186/2051-1426-2-S3-P88

Published: 6 November 2014

Patients with stable disease (SD) following cancer treatment have traditionally not been considered responders. We, and others, have previously shown that SD is an important response criteria in cancer patients treated with HD IL-2 immunotherapy [15]. Here we summarize findings from 13 sites, including 97 mRCC and 170 mM patients enrolled in the retrospective cohort of a national HD IL-2 database (http://www.proclaimregistry.com). Patients in the database were enrolled between 2006-2011, in an era of immune checkpoint inhibitors and targeted therapies. In metastatic renal cell carcinoma (mRCC) the median overall survival (mOS) was not reached in patients assessed to have SD post HD IL-2 (Figure 1). The mOS was over 2.5 years in patients with stable disease with metastatic melanoma (mM). The median follow-up for both diseases was 3 years. We further sought to examine whether patients with SD after 1 course, received benefit with additional HD IL-2 treatment. In mRCC patients that did not respond to treatment but continued onto another cycle of HD IL-2, the mOS was not reached and was statistically significant from patients that stopped treatment (p = 0.0269) (Figure 2).
Figure 1

Time Since First Dose of IL-2, Months.

Figure 2

Time Since First Dose of IL-2, Months.

Discussion

Unlike chemotherapy and targeted therapies, immunotherapeutics have the unique potential to achieve long lasting durable responses in cancer. The continual homeostasis between the immune system and the tumor requires constant immune pressure, and tipping the balance toward the immune system using immunotherapy may be important. Registries such as PROCLAIMSM provide data which may guide the optimal sequencing of therapies and/or prioritization of randomized clinical trials [6].

Conclusion

We conclude that stable disease is durable and should be considered a valuable end point. Consolidation of this response with additional HD IL-2 treatment following SD may be important.

Authors’ Affiliations

(1)
Rutgers Cancer Institute of New Jersey
(2)
Prometheus Laboratory
(3)
Duke University
(4)
Department of Medicine, University of Southern California
(5)
Prometheus Laboratory
(6)
Moores Cancer Center
(7)
Beth Israel Hospital Deaconess Medical Center

References

  1. Payne R, Glenn L, Hoen H, Richards B, Smith JW, Lufkin R, Crocenzi TS, Urba WJ, Curti BD: Durable responses and reversibile toxicity of high-dose interleukin 2 treatment of melanoma and renal cancer in a community hospital biotherapy program. 2014, 2: 13-doi:10.1186/2051-1426-2-13Google Scholar
  2. Merriman J et al.: Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). ASCO 2014. J Clin Oncol. 2014, 32: 5s-10.1200/JCO.2013.49.4757. (suppl; abstr 4577)View ArticleGoogle Scholar
  3. Morse M et al.: High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR). ASCO 2014. J Clin Oncol. 2014, 32: 5s-10.1200/JCO.2013.49.4757. (suppl; abstr 4523)View ArticleGoogle Scholar
  4. Daniels G et al.: Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry. ASCO 2014. J Clin Oncol. 2014, 32: 5s-10.1200/JCO.2013.49.4757. (suppl; abstr 9054)View ArticleGoogle Scholar
  5. Hughes T, Iodice G, Basu S, Fung H, Maciejewski J, Nathan S, Rich E, Bines S, Kaufman H et al.: Clinical Benefit of High Dose IL-2 (HD IL-2) Therapy Depends on the Kinetics of Response: Evidence for Improved Overall Survival in Patients with Stable Disease. (submitted to Cancer Immunology Immunotherapy)Google Scholar
  6. Kaufman HL, Wong KK, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA: The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). Journal of Personalized Medicine. 2014, 4: 52-64. 10.3390/jpm4010052.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Kaufman et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement